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Letters to the Editor 177Diagnostic accuracy of a TRAIL, IP-10 and
CRP combination for discriminating
bacterial and viral etiologies at the
Emergency Department
Dear Editor,
We read with interest the review article by ten Oever et
al., on immune response-derived biomarkers in the differ-
ential diagnosis of inflammatory disorders1 and the related
comment by van der Does et al., who reported a retrospec-
tive study indicating that TRAIL and IP-10 represent candi-
dates for biomarkers of viral infections in the Emergency
Department (ED).2 Here we confirm this finding and show
that a signature combining the viral-induced proteins TRAIL
and IP-10 with the classical bacterial-induced biomarker
CRP is highly discriminatory for ED patients presenting
with microbiologically confirmed bacterial and viral infec-
tions. Further, using adjudication of an expert panel to
expand the reference standard3,4 we provide support that
the differential diagnostic performance of this three-
biomarker signature is robust across a broad ED population
resembling that found in the clinical setting.
A major challenge underlying effective management of
febrile ED patients is the difficulty in clinically distinguish-
ing between bacterial and viral etiologies highlighted by
ten Oever et al.1 This clinical uncertainty drives antibiotic
misuse, both underuse and overuse, with detrimental ram-
ifications for the patient, healthcare system and society,
including emergence of antibiotic resistance. While routine
diagnostic tests for pathogen detection may aid in deter-
mining infection etiology, they often are limited by one or
more of the following key limitations: (i) lengthy time to
result; (ii) inability to diagnose infections that are not
readily accessible (e.g., pneumonia); (iii) uncertainty
regarding the clinical interpretation of a viral identifica-
tion, which does not preclude the possibility of a bacterial
co-infection; and (iv) false alarms due to the presence
(“carriage”) of potentially pathogenic microbes that are
also part of the natural flora (e.g., Streptococcus pneumo-
niae). Host-based biomarker approaches represent a prom-
ising complement to pathogen-based diagnostics, as
immune components circulate throughout the body and a
distinct response is elicited when a disease-causing path-
ogen is encountered.
Here we describe a sub-study of the Curiosity study that
was conducted prospectively between August 2009 and
November 2013 at two Medical Centers in Israel
(NCT01917461). The Curiosity study identified and validated
a novel host-biomarker signature for differential diagnosis of
acute bacterial and viral infections. The heterogeneous
study population comprised febrile inpatients and ED ar-
rivals, both children and adults, presenting with diverse clin-
ical syndromes and a variety of pathogens and up to 7 days
of symptoms. The optimally performing signature was found
to be computational integration of the concentrations of
three blood-borne proteins: TRAIL, IP-10 and CRP.5
The aim of this sub-study was to evaluate the diagnostic
performance of the same signature and constituent bio-
markers in the sub-population of ED patients. The reference
Figure 1 The host proteins TRAIL, IP-10 and CRP and combinatorial signature are differentially expressed in patients presenting
with bacterial and viral infections. Box plots for TRAIL, IP-10, CRP, and host-signature measured over the microbiologically
confirmed cohort (n Z 155) are presented. Red line and circle correspond to group median and average respectively.
178 Letters to the Editorstandard was based on microbiological confirmation plus
adjudication by an expert panel after review of all partic-
ipant clinical, laboratory, radiological, microbiological and
follow-up data. Each panel member independently assigned
one of the following diagnostic labels to a patient: (i)
bacterial (including mixed bacterial and viral co-infection);
(ii) viral; or (iii) unknown. A “true diagnosis” required
positive microbiological confirmation plus a unanimous
expert panel, i.e., all three panel members independentlyTable 1A Diagnostic performance of the individual biomarkers a
confirmed reference standard (nbacterialZ 27, nviralZ 128). The f
TRAIL, IP-10 and CRP respectively. The signature assigned equivoc
Accuracy measure TRAIL IP-10
Sensitivity 89% [71%, 98%] 74% [54%,
Specificity 84% [76%, 90%] 66% [58%,
LRþ 5.42 [3.58, 8.19] 2.20 [1.58,
LR 0.13 [0.05, 0.39] 0.39 [0.20,
PPV 53% [38%, 68%] 32% [21%,
NPV 97% [92%, 99%] 92% [85%,
[] Z 95% Confidence interval.
Table 1B Diagnostic performance of the individual biomarkers a
panel adjudication reference standard (nbacterialZ 103, nviralZ 20
used for TRAIL, IP-10 and CRP respectively. The signature assigne
patients.
Accuracy measure TRAIL IP-10
Sensitivity 86% [78%, 92%] 66% [56%,
Specificity 82% [76%, 87%] 65% [58%,
LRþ 4.76 [3.52, 6.44] 1.90 [1.50,
LR- 0.17 [0.10, 0.27] 0.52 [0.39,
PPV 71% [62%, 78%] 49% [40%,
NPV 92% [87%, 96%] 79% [72%,
[] Z 95% Confidence interval.assigned bacterial or viral etiology. The inclusion and
exclusion criteria, recruitment process, data collection,
sample analysis and criteria for microbiological confirmation
were described previously.5 The expert panel was blinded to
the test result and test performers were blinded to the
reference standard. Predefined cut-offs were applied for
each of the biomarkers as follows: TRAIL, 70 pg/ml; IP-10,
500 pg/ml; and CRP, 40 mg/L. For the host-signature test,
as defined previously,5 pre-determined cut-offs werend a combinatorial signature compared to a microbiologically
ollowing cut-offs 70 pg/ml, 500 pg/ml, 40 mg/L were used for
al results to 15% of the bacterial and 9% of the viral patients.
CRP Signature
89%] 70% [50%, 86%] 96% [78%, 100%]
75%] 77% [69%, 84%] 93% [87%, 97%]
3.07] 3.11 [2.08, 4.65] 13.99 [7.13, 27.46]
0.75] 0.38 [0.21, 0.69] 0.05 [0.01, 0.32]
45%] 40% [26%, 55%] 73% [54%, 88%]
97%] 93% [86%, 97%] 99% [95%, 100%]
nd a combinatorial signature compared to a unanimous expert
4). The following cut-offs 70 pg/ml, 500 pg/ml, 40 mg/L were
d equivocal results to 14% of the bacterial and 7% of the viral
CRP Signature
75%] 78% [68%, 85%] 90% [82%, 95%]
72%] 80% [74%, 86%] 94% [89%, 97%]
2.40] 3.96 [2.94, 5.33] 14.16 [8.15, 24.59]
0.69] 0.28 [0.19, 0.40] 0.11 [0.06, 0.20]
58%] 67% [57%, 75%] 87% [78%, 93%]
85%] 88% [82%, 92%] 95% [91%, 98%]
Letters to the Editor 179employed such that the test gives three results: viral (score
0e35), equivocal (score 35e65) or bacterial (score 65e100).
Of the 744 participants that met the Curiosity study
infectious disease inclusion criteria, 428 participants with
suspected infections were recruited at the ED, of which 155
had a confirmed etiology (128 viral and 27 bacterial [or
mixed co-infection]). In agreement with the Curiosity study
and van der Does et al., all three biomarkers were
significantly differentially expressed between bacterial
and viral infections: TRAIL (rank-sum P < 1011), IP-10
(rank-sum P < 104), and CRP (rank-sum P < 108) (Fig.
1). Notably, the combinatorial signature of all three bio-
markers exhibited the greatest diagnostic accuracy,
yielding a sensitivity of 96% [95% confidence interval: 78%,
100%] and specificity of 93% [87%, 97%], significantly better
than the individual proteins (see Table 1A). Furthermore,
the signature outperformed routine lab parameters such
as white blood cell count (sensitivity 56% [35%, 75%] and
specificity 84% [77%, 90%]; cut-off 15,000 cells/ml) and ab-
solute neutrophil count (sensitivity 59% [39%, 78%] and
specificity 88% [81%, 93%]; cut-off 10,000 cells/ml).
Often, the laboratory testing of patients with an infec-
tious etiology does not yield a definitive microbiological
confirmation. To examine the signature performance in
such cases, we broadened the reference standard by
removing the requirement of microbiological confirmation,
and based it on unanimous expert panel adjudication.
Application of this reference standard resulted in an
extended cohort of 307 patients (204 viral and 103 bacte-
rial [or mixed co-infection]). The signature exhibited a
sensitivity of 90% [82%, 95%] and specificity of 94% [89%,
97%], again significantly outperforming the individual bio-
markers and clinical parameters (see Table 1B), thereby
supporting the generalizability of the diagnostic perfor-
mance results.
In conclusion, the diagnostic performance data re-
ported here support that a host-biomarker signature
comprising TRAIL, IP-10 and CRP represents a promising
new tool for aiding ED clinicians in determining the bac-
terial versus viral etiology of infectious disease. The
increased diagnostic accuracy may be attributed to the
combination of both viral- and bacterial-induced proteins,
which complement one another. This actionable informa-
tion has the potential to support the clinician in deciding
whether to prescribe antibiotics. Future clinical studies
are required to examine the usefulness of this host-
biomarker signature in safely decreasing unnecessary
antibiotic prescription at the ED.
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